GPC3 and hepatocellular carcinoma: Wang et al. [20] constructed a modified CAR-T cell targeting glypican-3 (GPC3) in hepatocellular carcinoma (HCC).This modification involved substituting the cd8α-derived hinge region in the conventional CAR structure with a 4-1bb-derived hinge region containing 11 cysteine residues.